#ganx

Listen/purchase: COVERS CS by POLLEN

Market Tide Weekly — Tuesday Edition: June 30, 2026

The market is not just rewarding the fastest movers this week; it is rewarding companies that can show a credible reset in the filings. NNBR, GANX, and AZI each crossed an important threshold without eliminating the risk. That is the setup: survival mode is ending, but prove-it mode is just beginning.

Tuesday Edition — June 30, 2026 This week’s edition is about small-cap companies trying to cross a difficult line: from survival mode into prove-it mode. The strongest filing signals are not clean momentum stories. They are resets — companies trying to turn balance-sheet repair, governance change, clinical progress, commercial contracts, or operating inflection into something more durable.

The opportunity in this kind of market is rarely obvious from price action alone. The real signal is in the filings: which companies cleaned up capital structures, which ones gained regulatory or commercial traction, which ones strengthened governance, and which ones still need too much dilution or execution to make the story work. This week’s public slate — NNBR, AZI, and GANX — captures three different versions of that same prove-it setup.

Reader Mode Skim Layer

· Main theme: This week is about small-cap reset stories moving from survival mode into prove-it mode.

· Public slate: NNBR, GANX, and AZI each show a filing-driven catalyst, but each still carries unresolved execution, financing, or validation risk.

· Subscriber slate: TYGO and WSHP add two gated contrasts: one cleaner turnaround-to-scaling case and one high-novelty social-commerce structure.

· Deep Dive: GANX is selected for Thursday because the Lighthouse Report showed a biotech/healthcare swell and GANX has a fresh FDA IND authorization catalyst.

· Visual anchor: The Structural Signals Map should show each company’s reset type, strongest signal, and main watch item.

· Reader takeaway: These are not finished turnarounds; the filings moved the burden of proof forward, but execution still decides the outcome.

Public Slate at a Glance

Markdown Table — Public Slate at a Glance | Public Pick | One-Sentence Thesis | One-Sentence Risk Qualifier | | — -| — -| — -| | NNBR | NNBR is trying to turn a completed industrial restructuring into launch-driven growth, supported by margin expansion, Power Solutions strength, governance alignment, and an active capital-structure workstream. | The equity thesis remains constrained by leverage, preferred-stock overhang, cash conversion, Mobile Solutions stabilization, and CFO-transition timing. | | AZI | AZI is a speculative survival-to-growth reset where a revenue pivot into auto parts, founder support, Nasdaq compliance recovery, and June commercial agreements support the turnaround narrative. | The setup remains high-risk because of going-concern pressure, extreme dilution, insider voting control, reverse-split authority, thin margins, and reporting-governance sensitivity. | | GANX | GANX moved from broad biotech optionality into a clearer Parkinson’s Phase 2 catalyst after FDA authorization of the GT-02287 IND. | The thesis is still binary and financing-sensitive because Phase 1b open-label signals must translate into controlled Phase 2 evidence. |

Why This Week Matters

The common thread this week is transition risk. Each company has done something meaningful enough to deserve attention, but none has eliminated the hard part. NNBR still has to turn launches and governance alignment into balance-sheet progress. AZI still has to prove that its auto-parts platform can outgrow its dilution and governance baggage. GANX still has to translate early Parkinson’s signals into a real Phase 2 development case. That is why this edition is less about declaring winners and more about identifying which filings moved the burden of proof forward.

Why These Three Picks Belong Together

NNBR, AZI, and GANX are very different businesses, but the filing setup is similar: each one has crossed an important threshold without reaching the finish line. NNBR has operating momentum and a more aligned governance structure, but the balance sheet still matters. AZI has revenue growth, founder support, and fresh commercial activity, but the capital structure remains messy. GANX has a cleaner regulatory path after FDA authorization of the GT-02287 IND, but the clinical thesis still needs controlled Phase 2 validation. That mix — real progress plus unresolved risk — is the heart of this week’s public slate.

How We Read the Filing Stack

The analysis below is distilled from the separate filing-summary documents prepared for this edition. Instead of reproducing raw filing notes, each section translates the filing stack into the questions readers actually need answered: what changed, why it matters, what still has to be proven, and what could break the thesis.

Markdown Table — Filing Stack Map | Ticker | Primary Filing Layer | Key Signal | Reader Framing | | — -| — -| — -| — -| | NNBR | 10-K, 10-Q, 8-Ks, investor decks, credit amendments, governance filings | Transformation-to-scaling, Power Solutions strength, activist-aligned governance, capital-structure workstream | Leveraged industrial turnaround with credible operating momentum but balance-sheet overhang. | | AZI | 6-Ks, 20-F, proxy/charter filings, financing agreements, Nasdaq notices, material contracts | Revenue pivot, liquidity repair, Nasdaq recovery, founder support, commercial-contract activity | Foreign-issuer survival-to-growth reset with high dilution and governance risk. | | GANX | 8-Ks, 10-K, 10-Q, clinical presentations, financing filings | FDA IND authorization for GT-02287 and Phase 2a Parkinson’s path | Clinical-regulatory catalyst with binary biotech and financing risk. | | TYGO | 8-Ks, earnings releases, supply agreement, financing filings, leadership/governance updates | Debt elimination, profitability inflection, Q1 confirmation, revolver access | Cleaner subscriber-side turnaround-to-scaling setup. | | WSHP | 20-F, 6-Ks, F-1/8-A12B, 424B filings, S-8, CEO-transition filing | ShareBack/WePoints structure, CEO reset, post-listing proof period | High-novelty social-commerce structure that still needs operating validation. |

Pick Slate

Markdown Table — Pick Slate | Slot | Pick | Distribution | Why It Made the Slate | Operator Check | | — -| — -| — -| — -| — -| | Public Pick 1 | NNBR | Public | Best industrial operating turnaround signal: launch wave, margin improvement, governance alignment, and capital-structure optionality. | Confirmed: no operator position. | | Public Pick 2 | AZI | Public | Highest-risk reset story with major filing activity: revenue pivot, Nasdaq recovery, founder support, and material commercial agreements. | Confirmed: no operator position. | | Public Pick 3 | GANX | Public | Clinical-regulatory catalyst upgraded after FDA authorization of the GT-02287 IND and expected Phase 2a initiation path. | Confirmed: no operator position. | | Subscriber Pick 1 | TYGO | Email-subscriber | Cleaner turnaround-to-scaling setup with debt elimination, positive operating signals, lender validation, and Q1 confirmation. | Confirmed: no operator position. | | Subscriber Pick 2 | WSHP | Email-subscriber | High-novelty foreign-issuer structure built around ShareBack, WePoints, and a CEO commercialization reset. | Confirmed: no operator position. |

With that framework in place, the public section starts with the most operating-heavy reset in the group: NNBR. From there, the slate moves to GANX, where the catalyst is clinical and regulatory, and then to AZI, where the upside is tied to survival, capital access, and commercial follow-through.

Public Picks

NNBR — NN Inc.

Overview: NNBR is a leveraged industrial turnaround candidate with a cleaner operating story than the balance sheet initially suggests. The company has moved from restructuring into early-stage scaling, supported by a 2026 launch wave, improving margins, a more focused commercial engine, and strong momentum in Power Solutions. Its recent trading signal is not just price action; it is tied to a filing arc that shows revenue growth, margin expansion, governance stabilization, lender flexibility, and a capital-structure workstream that remains central to the equity thesis.

Structural Signals: The clearest structural signal is the transition from transformation to scaling. NNBR’s filing package shows approximately 100 programs launching in 2026, an $800 million-plus commercial pipeline, and new business wins guided to $80 million to $90 million after an April guidance increase (NN, Inc., Form 8-K and Exhibit 99.1: Preliminary Q1 2026 Results and Guidance Increase, 14 Apr. 2026). Power Solutions remains the profitability anchor, with exposure to electrical distribution, defense, electronics, medical, and data-center markets (NN, Inc., Form 8-K and Exhibits 99.1–99.2: Q1 2026 Earnings Release and Investor Presentation, 6 May 2026). The Legion Partners cooperation agreement, Raymond T. White’s board appointment, and Strategic Committee role create a more shareholder-aligned governance structure during a period when refinancing, strategic alternatives, and capital allocation matter (NN, Inc., Form 8-K and Exhibit 10.1: Cooperation Agreement with Legion Partners, 20 Jan. 2026; NN, Inc., Form 8-K: Strategic Committee Membership Update, 6 Apr. 2026).

Financial Signals: Q1 2026 provides the strongest current evidence. Net sales were $110.4 million, up 6.3% year over year; adjusted gross margin reached 18.9%; adjusted EBITDA rose 7.8% to $13.8 million; and adjusted operating income rose 9% to $3.6 million. Power Solutions generated $48.2 million of sales, up 12.1%, and $6.8 million of adjusted EBITDA, up 14%. Mobile Solutions also stabilized, with $62.2 million of sales, up 2.1%, and $7.0 million of adjusted EBITDA, up 3% (NN, Inc., Form 8-K and Exhibits 99.1–99.2: Q1 2026 Earnings Release and Investor Presentation, 6 May 2026). The tension is that the operating improvement still sits beside negative operating cash flow, elevated debt, material interest expense, Series D preferred stock, and declining book equity (NN, Inc., Form 10-Q, 6 May 2026).

Risk Profile: NNBR is not a clean growth story; it is a leveraged execution story. The main risks are cash conversion, leverage, preferred-stock overhang, Mobile Solutions stabilization, auto and commercial-vehicle cyclicality, customer concentration, commodity and precious-metal exposure, covenant sensitivity, CFO transition timing, and whether the Strategic Committee can translate governance alignment into tangible capital-structure progress (NN, Inc., Form 10-Q, 6 May 2026; NN, Inc., Form 8-K: Strategic Committee Membership Update, 6 Apr. 2026). The CFO departure includes no-disagreement language and interim continuity, but it still arrives during an active launch year and capital-structure review (NN, Inc., Form 8-K: Executive Leadership Change, 22 June 2026).

Forward Scenarios: The constructive scenario is that NNBR converts the 2026 launch wave into revenue growth, keeps margins expanding, uses lender flexibility to support working capital, and advances refinancing or strategic alternatives that reduce the preferred-stock and leverage overhang. The downside scenario is that cash conversion lags, Mobile Solutions remains uneven, end-market cyclicality offsets Power Solutions strength, or the capital-structure review fails to produce balance-sheet relief quickly enough. Bottom line: NNBR has credible operating momentum, but the equity setup depends on execution, liquidity discipline, and balance-sheet progress.

NNBR is the cleanest industrial example of this week’s theme: enough operating momentum to matter, but not enough balance-sheet progress yet to call the turnaround complete. The next public pick shifts from industrial execution to biotech validation.

GANX — Gain Therapeutics Inc.

Overview: GANX is a clinical-stage biotech whose setup has shifted from broad early-stage optionality into a clearer Parkinson’s disease Phase 2 catalyst. The center of the thesis is GT-02287, an orally administered, brain-penetrant allosteric enzyme modulator intended to restore glucocerebrosidase function in Parkinson’s disease with or without a GBA1 mutation (Gain Therapeutics, Inc., Form 8-K and Exhibit 99.1: Q4/FY2025 Results and Corporate Update, 26 Mar. 2026). The June 29, 2026 FDA authorization of the GT-02287 IND is the key filing event because it allows the company to move from Australian Phase 1a/1b work into U.S.-enabled Phase 2a development (Gain Therapeutics, Inc., Form 8-K: FDA Authorization of GT-02287 IND, 29 June 2026).

Structural Signals: The clinical evidence chain is unusually coherent for a small-cap biotech. Enrollment reached target-range momentum in 2025, Data Monitoring Committee reviews supported continuation without dose-level changes, and the Phase 1b extension kept patients on study beyond the initial 90-day dosing period (Gain Therapeutics, Inc., Form 8-K: Phase 1b GT-02287 Enrollment and Biomarker-Timing Update, 30 June 2025; Gain Therapeutics, Inc., Form 8-K and Exhibit 99.1: Early Phase 1b GT-02287 Clinical Update, 12 Aug. 2025). GANX later reported that elevated-baseline CSF glucosylsphingosine participants showed biomarker improvement, MDS-UPDRS stability or improvement signals, and a stronger Day 150 subgroup read-through than low-baseline participants (Gain Therapeutics, Inc., Form 8-K: Phase 1b GT-02287 Exploratory Biomarker Results, 18 Dec. 2025; Gain Therapeutics, Inc., Form 8-K: Interim Phase 1b Extension Data, 26 May 2026). The May 2026 extension update also showed that Phase 2 endpoint planning was being shaped around smell and gait measures, including UPSIT smell testing and Opal wearable gait sensors (Gain Therapeutics, Inc., Form 8-K: Interim Phase 1b Extension Data, 26 May 2026).

Financial Signals: GANX remains pre-commercial, with no product revenue and a valuation still driven by pipeline progress, clinical timing, and financing access (Gain Therapeutics, Inc., Form 10-K, 26 Mar. 2026). FY2025 cash, cash equivalents, and marketable securities were $20.8 million at year-end, rising from $10.4 million the prior year, but Q1 2026 cash declined to $16.5 million as R&D and public-company costs continued. Q1 2026 R&D expense increased to $2.8 million and G&A increased to $2.6 million, while net loss was $5.6 million (Gain Therapeutics, Inc., Form 8-K and Exhibit 99.1: Q1 2026 Results and Corporate Update, 11 May 2026). The company has used equity financing, an ATM program, warrants, and registered-direct/private-placement structures to support clinical runway, so liquidity has improved at the cost of dilution and warrant overhang (Gain Therapeutics, Inc., Form 8-K: Underwritten Public Offering and Warrant Financing, 17 July 2025).

Risk Profile: GANX is a binary biotech setup. The main risks are Phase 2 trial execution, enrollment timing, whether open-label Phase 1b signals translate into controlled data, biomarker interpretation, regulatory feedback, CMC and manufacturing execution, cash runway, future financing needs, and dilution from ATM, warrant, and equity-incentive capacity (Gain Therapeutics, Inc., Form 10-K, 26 Mar. 2026; Gain Therapeutics, Inc., Form 10-Q, 11 May 2026). The FDA IND authorization improves program credibility, but it does not eliminate clinical failure risk or the likelihood that more capital will be needed before commercialization is visible (Gain Therapeutics, Inc., Form 8-K: FDA Authorization of GT-02287 IND, 29 June 2026).

Forward Scenarios: The constructive scenario is that GANX initiates the Phase 2a study in Q3 2026, successfully opens U.S., Australian, and selected European sites, converts the GT-02287 biomarker and clinical-score signals into a more rigorous efficacy narrative, and uses the GT-04686 preclinical program as a secondary GCase-platform support signal (Gain Therapeutics, Inc., Form 8-K: FDA Authorization of GT-02287 IND, 29 June 2026; Gain Therapeutics, Inc., Form 8-K: AD/PD 2026 Clinical and Biomarker Presentation, 18 Mar. 2026). The downside scenario is that enrollment lags, Phase 2 results fail to confirm Phase 1b signals, financing pressure returns before value-creating data, or dilution overwhelms the clinical catalyst. Bottom line: GANX now has a real clinical-regulatory catalyst, but it remains a high-risk, financing-sensitive Parkinson’s disease development story.

GANX brings a different kind of prove-it setup. The company now has a clearer regulatory path, but clinical-stage biotech progress remains binary until controlled data confirms the signal. The third public pick moves from clinical validation to capital-market survival and commercial reset.

AZI — Autozi Internet Technology (Global) Ltd.

Overview: AZI is a high-volatility foreign-issuer turnaround setup built around a sharp pivot from lower-margin automotive services into an auto-parts, electrification, and supply-chain platform strategy. The filing record shows real revenue growth and a clearer strategic roadmap, but it also shows the classic microcap survival tradeoff: liquidity repair, dilution, reverse-split authority, insider control, and execution risk all sit directly beside the growth narrative.

Structural Signals: The most important structural signal is that AZI moved from crisis management toward a survival-to-growth reset. First-half FY2025 revenue rose to $79.9 million, up 65.9% year over year, with auto parts and accessories representing 98.7% of revenue, confirming a decisive business-model pivot (Autozi Internet Technology (Global) Ltd., Exhibit 99.1 to Form 6-K: First Half FY2025 Results and Chairman’s Letter, 5 Sept. 2025). Management framed the next phase around electrification and servicization: EV component exposure, digital supply-chain tools, SaaS/cloud infrastructure, globalization, and a broader automotive maintenance-parts platform (Autozi Internet Technology (Global) Ltd., Exhibit 99.1 to Form 6-K: First Half FY2025 Results and Chairman’s Letter, 5 Sept. 2025). June 2026 material commercial agreements add credibility because they create binding commercial obligations, potential revenue pathways, and evidence that the growth strategy is moving beyond narrative (Autozi Internet Technology (Global) Ltd., Exhibit 10.1 to Form 6-K: Material Commercial Agreement, 25 June 2026; Autozi Internet Technology (Global) Ltd., Form 6-K and Exhibit 10.1, 26 June 2026).

Financial and Capital-Structure Signals: AZI’s financial profile is still stressed. The interim filing showed gross margin of only 1.7%, operating loss of $8.1 million, net loss of $5.3 million, cash of only $349,000, negative working capital of approximately $19 million, accumulated deficit of $134.8 million, and substantial doubt about the company’s ability to continue as a going concern (Autozi Internet Technology (Global) Ltd., Exhibit 99.2 to Form 6-K: Unaudited Interim Condensed Consolidated Financial Statements, 6 Dec. 2025). To stabilize, AZI cleaned up a toxic JAK financing structure by replacing a potential $24 million warrant-driven overhang with a smaller $1.53 million 0% convertible note, then raised more than $50 million through December private placements at ultra-low pricing (Autozi Internet Technology (Global) Ltd., Exhibit 99.2 to Form 6-K: Waiver and Release Agreement, 22 Sept. 2025; Autozi Internet Technology (Global) Ltd., Form 6-K and Exhibit 99.1: $18.3 Million Private Placement Announcement, 6 Dec. 2025; Autozi Internet Technology (Global) Ltd., Form 6-K: $31.9 Million Private Placement, 9 Dec. 2025). The structure was cleaner than many toxic convertible structures, but the dilution was extreme.

Governance and Market-Structure Signals: AZI’s governance reset is central to the thesis. The company increased Class B voting rights to 200 votes per share, authorized reverse splits, completed a 50-for-1 reverse split, later received authorization for share consolidation up to 5,000-for-1, and regained Nasdaq compliance after deficiency notices and a delisting threat (Autozi Internet Technology (Global) Ltd., Form 6-K: Extraordinary General Meeting / Share Consolidation Authorization, 9 Feb. 2026; Autozi Internet Technology (Global) Ltd., Form 6-K and Exhibit 99.1: Nasdaq Compliance Regained, 14 Jan. 2026). Founder Dr. Zhang Houqi’s commitment to purchase $10 million to $30 million of shares at $5.00 per share is a high-signal insider-confidence and capital-support marker (Autozi Internet Technology (Global) Ltd., Form 6-K and Exhibit 99.1: Founder Share Purchase Commitment, 29 Jan. 2026). However, the same filing arc also shows governance concentration, public-shareholder voting dilution, CFO and board turnover, a COO/CFO dual-role appointment, and an auditor-change event that keeps financial-reporting credibility under watch (Autozi Internet Technology (Global) Ltd., Form 6-K: Major Governance Change, 21 Apr. 2026; Autozi Internet Technology (Global) Ltd., Form 6-K and Exhibit 16.1: Auditor Change Letter, 10 June 2026).

Risk Profile: AZI is not a clean revenue-growth story; it is a capital-dependent foreign-issuer reset. The main risks are going-concern pressure, thin margins, operating losses, dilution from past and future financing, reverse-split volatility, insider-control concentration, auditor and CFO transition risk, supply-chain execution, PRC and cross-border regulatory complexity, dependence on capital markets, and whether the auto-parts platform can convert scale into durable gross margin and cash flow (Autozi Internet Technology (Global) Ltd., Form 20-F, 12 Feb. 2026; Autozi Internet Technology (Global) Ltd., Form 6-K: Major Governance Change, 21 Apr. 2026). The June commercial agreements help the operating case, but they do not yet resolve the balance-sheet and governance risks.

Forward Scenarios: The constructive scenario is that AZI uses the December capital raises, Nasdaq compliance recovery, founder purchase commitment, and June commercial contracts to prove the auto-parts, electrification, and servicization roadmap can generate higher-quality revenue and improved cash flow (Autozi Internet Technology (Global) Ltd., Form 6-K and Exhibit 99.1: Nasdaq Compliance Regained, 14 Jan. 2026; Autozi Internet Technology (Global) Ltd., Form 6-K and Exhibit 99.1: Founder Share Purchase Commitment, 29 Jan. 2026; Autozi Internet Technology (Global) Ltd., Exhibit 10.1 to Form 6-K: Material Commercial Agreement, 25 June 2026). The downside scenario is that dilution, weak margins, governance concentration, auditor/CFO transition concerns, and future financing needs overwhelm commercial progress. Bottom line: AZI has one of the strongest momentum and filing-event profiles in the slate, but the thesis must be framed as a speculative survival-to-growth reset rather than a straightforward operating turnaround.

That makes the public slate intentionally varied: one industrial launch-and-balance-sheet story, one biotech regulatory story, and one foreign-issuer survival-to-growth story. For readers who want the full five-name slate, the subscriber section adds two more complicated but useful contrasts.

Subscriber-Only Picks

Subscriber-Only: The public edition ends with NNBR, GANX, and AZI. Subscribers also receive TYGO and WSHP. TYGO is the cleaner turnaround-to-scaling contrast: debt eliminated, lender validation added, and Q1 momentum confirmed. WSHP is the high-novelty contrast: a social-commerce platform with an equity-linked loyalty structure that could be differentiated, but still needs proof of user, merchant, and revenue traction.

Continuity Modules

· What Changed: GANX’s setup strengthened after FDA authorization of the GT-02287 IND, and the Lighthouse Report showed healthcare as the largest visible speculative cluster, with biotechnology names dominating the signal zone. AZI’s June commercial-contract activity improved its operating proof layer, while TYGO’s filing arc continues to support a cleaner subscriber-side turnaround case.

· What I’m Watching: GANX Phase 2a initiation timing; whether biotech momentum persists across multiple sessions; whether GT-02287’s filing chain keeps separating GANX from broader low-price biotech churn; NNBR capital-structure updates; AZI commercial-contract follow-through; and TYGO operating-confirmation signals.

· Next Week Preview: The next edition should test whether this week’s reset stories show follow-through. The key question is whether filing-driven momentum is becoming durable execution or simply riding short-term speculative liquidity.

· Continuity Signals: Track whether the same signal zones repeat: healthcare/biotech breadth, small-cap technology follow-through, industrial turnaround strength, capital-structure cleanup, and companies moving from survival mode into measurable prove-it milestones.

Thursday Deep Dive: GANX

Selection Path: Screener-derived candidate, confirmed by the Lighthouse Report’s healthcare and biotech signal cluster. Subject: GANX — Gain Therapeutics Inc. Rationale: The June 28 Lighthouse Report showed healthcare as the largest visible cluster, with biotechnology and medical-device names dominating the speculative healthcare tape. GANX fits that swell because its own filing stack now has a fresh clinical-regulatory catalyst: FDA authorization of the GT-02287 IND and an expected Phase 2a Parkinson’s disease path (Gain Therapeutics, Inc., Form 8-K: FDA Authorization of GT-02287 IND, 29 June 2026). The Deep Dive should examine whether GANX is merely benefiting from biotech momentum or whether the filings show a differentiated catalyst chain strong enough to justify continued monitoring. Required Structure: Headline; The Setup; The Biotech Tape Context; The Filing Evidence; The Opportunity; Risks to the Thesis; What Would Confirm the Signal; MTW Bottom Line.

CTA and Share Layer

The public edition stops with NNBR, GANX, and AZI. Email subscribers receive the full five-name slate, including TYGO and WSHP, plus the Thursday Deep Dive when applicable. If this edition helped you see beyond the price move and into the filing structure, share it with someone who follows small-cap turnarounds, biotech catalysts, or capital-structure resets.

Disclosure and Selected Works Cited

Disclosure: Market Tide Weekly is provided for informational and educational purposes only. Nothing in this publication should be interpreted as investment advice, a recommendation to buy, sell, or hold any security, or a solicitation to engage in any investment transaction. Market Tide Weekly may discuss small-cap, micro-cap, speculative, foreign-issuer, clinical-stage biotechnology, or otherwise high-risk securities that can be volatile, illiquid, subject to wide bid-ask spreads, vulnerable to dilution, and unsuitable for many investors. Readers are responsible for conducting their own research and consulting a qualified financial, tax, or legal professional before making investment decisions.

The companies discussed in this edition — NNBR, AZI, GANX, TYGO, and WSHP — may have material risks, including but not limited to operating losses, going-concern warnings, financing dependency, dilution from equity or convertible securities, reverse splits or share consolidations, governance concentration, regulatory or clinical-trial uncertainty, supply-chain risk, customer concentration, capital-structure overhang, foreign-issuer reporting complexity, and limited trading liquidity. Discussion of any company’s filings, catalysts, price action, volume, or market position is not a prediction of future performance.

The operator has no investments or positions in NNBR, AZI, GANX, TYGO, or WSHP as of publication. If that status changes in the future, it should be disclosed in the applicable edition before publication. Readers should assume that securities mentioned may be subject to rapid price changes and that filing-based analysis can become outdated as new disclosures, financings, clinical updates, regulatory decisions, earnings releases, or corporate actions occur.

GANX is both a public pick in this edition and the selected Thursday Deep Dive subject. Repeated coverage should not be interpreted as increased conviction, a recommendation, or a prediction of future performance; it reflects the combination of a company-specific filing catalyst and the Lighthouse Report’s healthcare and biotech signal cluster.

Subscriber-only sections, when included, are intended for additional research context and do not constitute premium investment recommendations. The public edition and subscriber edition are both educational commentary based on available filings and market-level signal review. Past performance, recent price movement, trading volume, screener inclusion, or management commentary should not be relied upon as evidence of future results.

Selected Works Cited

Autozi Internet Technology (Global) Ltd. Exhibit 99.1 to Form 6-K: First Half FY2025 Results and Chairman’s Letter. U.S. Securities and Exchange Commission, 5 Sept. 2025.

Autozi Internet Technology (Global) Ltd. Exhibit 99.2 to Form 6-K: Waiver and Release Agreement. U.S. Securities and Exchange Commission, 22 Sept. 2025.

Autozi Internet Technology (Global) Ltd. Form 6-K and Exhibit 99.1: Two Nasdaq Deficiency Notices. U.S. Securities and Exchange Commission, 2 Dec. 2025.

Autozi Internet Technology (Global) Ltd. Form 6-K and Exhibit 99.1: $18.3 Million Private Placement Announcement. U.S. Securities and Exchange Commission, 6 Dec. 2025.

Autozi Internet Technology (Global) Ltd. Form 6-K: $31.9 Million Private Placement. U.S. Securities and Exchange Commission, 9 Dec. 2025.

Autozi Internet Technology (Global) Ltd. Exhibit 10.1 to Form 6-K: Securities Purchase Agreement. U.S. Securities and Exchange Commission, 9 Dec. 2025.

Autozi Internet Technology (Global) Ltd. Form 6-K and Exhibit 99.1: Nasdaq Compliance Regained. U.S. Securities and Exchange Commission, 14 Jan. 2026.

Autozi Internet Technology (Global) Ltd. Form 6-K and Exhibit 99.1: Founder Share Purchase Commitment. U.S. Securities and Exchange Commission, 29 Jan. 2026.

Autozi Internet Technology (Global) Ltd. Form 6-K: Extraordinary General Meeting / Share Consolidation Authorization. U.S. Securities and Exchange Commission, 9 Feb. 2026.

Autozi Internet Technology (Global) Ltd. Form 20-F. U.S. Securities and Exchange Commission, 12 Feb. 2026.

Autozi Internet Technology (Global) Ltd. Form 6-K: Major Governance Change. U.S. Securities and Exchange Commission, 21 Apr. 2026.

Autozi Internet Technology (Global) Ltd. Form 6-K and Exhibit 16.1: Auditor Change Letter. U.S. Securities and Exchange Commission, 10 June 2026.

Autozi Internet Technology (Global) Ltd. Form 6-K: Corporate Announcement. U.S. Securities and Exchange Commission, 25 June 2026.

Autozi Internet Technology (Global) Ltd. Exhibit 4.1 to Form 6-K: Instrument Defining Rights of Security Holders. U.S. Securities and Exchange Commission, 25 June 2026.

Autozi Internet Technology (Global) Ltd. Exhibit 10.1 to Form 6-K: Material Commercial Agreement. U.S. Securities and Exchange Commission, 25 June 2026.

Autozi Internet Technology (Global) Ltd. Exhibit 10.1 to Form 6-K: Material Commercial Agreement. U.S. Securities and Exchange Commission, 26 June 2026.

Gain Therapeutics, Inc. Form 8-K: Phase 1b GT-02287 Enrollment and Biomarker-Timing Update. U.S. Securities and Exchange Commission, 30 June 2025.

Gain Therapeutics, Inc. Form 8-K: Underwritten Public Offering and Warrant Financing. U.S. Securities and Exchange Commission, 17 July 2025.

Gain Therapeutics, Inc. Form 8-K and Exhibit 99.1: Early Phase 1b GT-02287 Clinical Update. U.S. Securities and Exchange Commission, 12 Aug. 2025.

Gain Therapeutics, Inc. Form 8-K: Major Phase 1b GT-02287 Clinical Update. U.S. Securities and Exchange Commission, 6 Oct. 2025.

Gain Therapeutics, Inc. Form 8-K: Phase 1b GT-02287 Exploratory Biomarker Results. U.S. Securities and Exchange Commission, 18 Dec. 2025.

Gain Therapeutics, Inc. Form 8-K: AD/PD 2026 Clinical and Biomarker Presentation. U.S. Securities and Exchange Commission, 18 Mar. 2026.

Gain Therapeutics, Inc. Form 8-K and Exhibit 99.1: Q4/FY2025 Results and Corporate Update. U.S. Securities and Exchange Commission, 26 Mar. 2026.

Gain Therapeutics, Inc. Form 10-K. U.S. Securities and Exchange Commission, 26 Mar. 2026.

Gain Therapeutics, Inc. Form 10-Q. U.S. Securities and Exchange Commission, 11 May 2026.

Gain Therapeutics, Inc. Form 8-K and Exhibit 99.1: Q1 2026 Results and Corporate Update. U.S. Securities and Exchange Commission, 11 May 2026.

Gain Therapeutics, Inc. Form 8-K: Interim Phase 1b Extension Data. U.S. Securities and Exchange Commission, 26 May 2026.

Gain Therapeutics, Inc. Form 8-K: Annual Meeting Voting Results. U.S. Securities and Exchange Commission, 25 June 2026.

Gain Therapeutics, Inc. Form 8-K: FDA Authorization of GT-02287 IND. U.S. Securities and Exchange Commission, 29 June 2026.

NN, Inc. Form 10-Q. U.S. Securities and Exchange Commission, 6 May 2026.

NN, Inc. Form 8-K and Exhibit 99.1: Electrical Distribution OEM Award Press Release. U.S. Securities and Exchange Commission, 12 Dec. 2025.

NN, Inc. Form 8-K and Exhibit 10.1: Cooperation Agreement with Legion Partners. U.S. Securities and Exchange Commission, 20 Jan. 2026.

NN, Inc. Form 8-K: Term Loan Amendment and Delayed Draw Term Loan. U.S. Securities and Exchange Commission, 30 Jan. 2026.

NN, Inc. Exhibit 10.1: Amendment №1 to Term Loan Credit Agreement. U.S. Securities and Exchange Commission, 30 Jan. 2026.

NN, Inc. Form 8-K and Exhibits 99.1–99.2: Q4 and Full-Year 2025 Earnings Release and Presentation. U.S. Securities and Exchange Commission, 4 Mar. 2026.

NN, Inc. Form 8-K: Strategic Committee Membership Update. U.S. Securities and Exchange Commission, 6 Apr. 2026.

NN, Inc. Form 8-K and Exhibit 99.1: Preliminary Q1 2026 Results and Guidance Increase. U.S. Securities and Exchange Commission, 14 Apr. 2026.

NN, Inc. Form 8-K and Exhibits 99.1–99.2: Q1 2026 Earnings Release and Investor Presentation. U.S. Securities and Exchange Commission, 6 May 2026.

NN, Inc. Exhibit 10.1: Material Contract / Credit Agreement Amendment. U.S. Securities and Exchange Commission, 3 June 2026.

NN, Inc. Form 8-K: Executive Leadership Change. U.S. Securities and Exchange Commission, 22 June 2026.

Tigo Energy, Inc. Form 8-K and Exhibit 10.1: Manufacturing and Supply Agreement with EG4 Electronics LLC. U.S. Securities and Exchange Commission, 25 Aug. 2025.

Tigo Energy, Inc. Form 8-K and Exhibit 10.1: $50 Million Convertible Promissory Note Financing. U.S. Securities and Exchange Commission, 31 Oct. 2025.

Tigo Energy, Inc. Form 8-K: Repayment and Termination of L1 Convertible Note. U.S. Securities and Exchange Commission, 17 Dec. 2025.

Tigo Energy, Inc. Form 8-K and Exhibit 99.1: Q4/FY2025 Earnings Release. U.S. Securities and Exchange Commission, 18 Dec. 2025.

Tigo Energy, Inc. Form 8-K: Wells Fargo Revolving Credit Facility. U.S. Securities and Exchange Commission, 2 Apr. 2026.

Tigo Energy, Inc. Form 8-K and Exhibit 99.1: Q1 2026 Earnings Release. U.S. Securities and Exchange Commission, 15 Apr. 2026.

Tigo Energy, Inc. Form 8-K: Appointment of Michael C. Potter as Chief Financial Officer. U.S. Securities and Exchange Commission, 26 Apr. 2026.

WeShop Holdings Ltd. Form F-1. U.S. Securities and Exchange Commission, 15 Sept. 2025.

WeShop Holdings Ltd. Form 6-K: F-1 Effectiveness, Capitalization Table, and Amended Articles. U.S. Securities and Exchange Commission, 13 Nov. 2025.

WeShop Holdings Ltd. Form 424B4: Final Prospectus for 12.5 Million WePoints. U.S. Securities and Exchange Commission, 19 Nov. 2025.

WeShop Holdings Ltd. Form 6-K: S-8 Option Registration and Investor Presentation. U.S. Securities and Exchange Commission, 5 Dec. 2025.

WeShop Holdings Ltd. Form S-8. U.S. Securities and Exchange Commission, 5 Dec. 2025.

WeShop Holdings Ltd. Form 424B3: Prospectus Supplements for WePoints and Class A Ordinary Share Resale Registration. U.S. Securities and Exchange Commission, 22 Dec. 2025.

WeShop Holdings Ltd. Form 6-K: FY2025 Results Press Release and Investor Presentation. U.S. Securities and Exchange Commission, 28 Apr. 2026.

WeShop Holdings Ltd. Form 20-F. U.S. Securities and Exchange Commission, 30 Apr. 2026.

WeShop Holdings Ltd. Form 6-K and Exhibit 99.1: CEO Appointment and Director Appointment. U.S. Securities and Exchange Commission, 17 June 2026.